Allogeneic autophagosome-enriched composition for the treatment of disease

Document Type

Patent

Publication Date

3-24-2020

Keywords

oregon; portland; chiles

Abstract

A method is presented for screening cells that produce allogeneic autophagosome enriched compositions able to induce expression of a selective marker on a subpopulation of peripheral blood mononuclear cells, the method comprising contacting a cell with a proteasome inhibitor, contacting the cell with a lysosome inhibitor, harvesting the resulting autophagosomes, determining a molecular signature of the harvested autophagosomes, and selecting cells that divert one or more Toll-like receptor agonist and/or one or more molecular chaperones to the harvested autophagosomes. By screening for cells that divert one or more Toll-like receptor agonist and/or one or more molecular chaperones to the harvested autophagosomes, enriched populations of autophagosomes may be generated which may illicit a specific immune response against numerous cancer types. In this way, an allogeneic, off-the-shelf cancer vaccine may be produced and made available to be administered in order to stimulate a targeted immune response in patients bearing different tumor types.

Area of Special Interest

Cancer

Specialty/Research Institute

Oncology

Specialty/Research Institute

Hematology

Location

United States

Comments

Patent Number: 10,597,731

Assignee

UbiVac, LLC (Portland, OR); Providence Health & Services-Oregon (Portland, OR)

Family ID

50485552

Serial Number

15/890,269

Link to Full Text

Share

COinS